VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Abatacept for prevention of acute GVHD

Abatacept is a selective inhibitor of T cell costimulation. Kirk Schultz, MD, British Columbia Children’s Hospital, Vancouver, Canada, discusses the use of abatacept for the treatment of acute graft-versus-host disease (GvHD), a major cause of death following unrelated-donor (URD) hematopoietic cell transplant (HCT). This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter